What's at stake for the next wave of coronavirus vaccines
Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and this week in healthcare news:
- We looked at how the next set of COVID-19 vaccine candidates are shaping up;
- A consolidation tsunami is headed for digital healthcare;
- We found 5 key takeaways from Bright Health's IPO filing.
If you're new to this newsletter, sign up here. Tips, comments? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...
The next wave of COVID-19 vaccines
As the rollout of three authorized vaccines continues here in the US, other drugmakers are still carrying on in their pursuits to arm the world with more effective shots.
Sanofi and GlaxoSmithKline on Monday said that their COVID-19 vaccine triggers a strong immune response, Andrew Dunn reports.
The companies are now looking at approval by the end of 2021.
Meanwhile, Novavax, which is close to getting the green light from the Food and Drug Administration for its coronavirus vaccine, still faces a key challenge.
Can it finish what it started?
Get the full story>>
Novavax could have the 'best' COVID-19 shot, but new delays are raising questions about the $10 billion biotech's path to profits
Digital health M&A is here
The funding boom for healthcare startups is, as you might expect, not slowing down just yet.
Healthcare startups raised $31.6 billion in the first three months of 2021, CB Insights reports.
Megan Hernbroth broke down the six investors making the most bets on digital health startups. Surprise, surprise: Tiger Global's at the top of the list.
All the funding is turning into M&A activity.
Most recently - Ro said on Wednesday that it's buying Modern Fertility.
It's a case of a well-funded startup (Ro) acquiring a smaller company (Modern Fertility) to keep growing.
And Ro isn't the only one acquiring. Cedar last week said it's buying rival Ooda Health, and Grand Rounds in March said that it's buying telehealth startup Dr. On Demand.
We're calling it the start of a "consolidation tsunami."
Find out more>>
Well-funded healthcare startups are snatching up smaller companies to keep growing. It's the start of a consolidation tsunami.
Bright Health is the latest insurer startup to go up for an IPO
Speaking of acquisitions - health insurer Bright Health filed to go public on Wednesday, and its filings provided our best look yet at how the company is growing.
A lot of that growth is coming from acquisitions of other companies.
Of the five health insurance startups we've been tracking for the past few years-Alignment, Bright, Clover, Devoted, and Oscar-there's only one left that hasn't started the going-public process (as far as we know): Devoted Health.
We'll still be looking over insurance filings to see how Devoted is doing.
For the full year 2020, Devoted's losses deepened as it took on more members.
Even so, there's nothing quite like getting a look at a company's S-1 filing.
Here are 5 takeaways from Bright's upcoming IPO>>
Health insurance startup Bright Health is going public. Its S-1 filing reveals its bonkers revenue growth, dealmaking spree, and a foray into clinics.
The fastest-growing biotechs
Allison DeAngelis and Andrew rounded up the fastest growing biotech companies.
The 29 firms included in their list hired hundreds of new workers in 2020 and grew by at least 50%.
It's a part of their project looking at biotech compensation, from median pay to the top-paid CEOs.
You can find it all their coverage here>>
INSIDE BIOTECH: See the drug companies that are growing the fastest and pay workers the most
More stories we covered this week:
- Allison broke down how to pitch a biotech venture fund that turns down 98% of startups.
- Patricia Kelly Yeo spoke to home-care operators, who tell her they're having a hard time finding workers in a tight labor market.
- Blake and finance reporter Samantha Stokes chronicled JPMorgan's latest attempt to disrupt healthcare, just three months after Haven folded.
- Dr. Catherine Schuster-Bruce has a great story on the potential for other mRNA medicines.
- Lydia
from Business Insider https://ift.tt/2SbC81a
No comments